Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rabbit Polyclonal (IgG) to Human CHUK / IKKA / IKK Alpha
Human, Mouse, Rat, Bovine
ICC, Western blot, Immunoprecipitation, ELISA
Human CHUK / IKKA / IKK Alpha
Human, Mouse, Rat, Bovine (tested or 100% immunogen sequence identity)
Protein A purified
Western blot (1:1000)
Specificity and Use
CHUK / IKKA / IKK Alpha antibody was raised against synthetic peptide corresponding to the 20 N-terminal amino acids of human IKK alpha (KLH coupled).
Detects total IKK alpha proteins. Detects IKK alpha only. Does not cross-react with IKK beta or IKK gamma. Species cross-reactivity: Human, mouse, and rat. Predicted to cross-react with bovine based on sequence homology.
Suitable for use in ELISA, Western Blot, Immunoprecipitation and Immunocytochemistry. Western Blot: 1:1000. Immunoprecipitation: 1:500. Immunocytochemistry (ABC): 1:200.
10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1 mg/ml BSA, 50% glycerol. No preservative added.
Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome.